<b>Gapping up <br/>In reaction to strong earnings/guidance:</b><br/>ALIM +20%, SQ +19.3%, ETRM +17.9%, XPO +12.3%, AXGN +11.4%, AVEO +9.6%, PODD +8.6%, EXEL +8.5%, NSTG +8.3%, JACK +7.8%, GDDY +7.7%, (also names new CFO), AKRX +7.6%, GOGO +7.1%<br/>AVID +6.4%, ERII +6.1%, EPE +6.1%, KTWO +6%, SNCR +5.9%, MX +5.9%, FXCM +5.5%, AV +5%, CSII +4.9%, CTB +4.6%, FIVN +4.5%, IO +4.4%, HSC +4.3%, SYN +4.2%, NSIT +4%<br/>COT +3.9%, DNR +3.8%, MASI +3.6%, NLST +3.3%, SXL +2.8%, HL +2.8%, NGL +2.8%, ICPT +2.6%, TROX +2.5%, EVA +2.5%, PE +2.4%, HLF +2.4%, EVC +2.4%, BTG +2.2%, CNAT +2.1%, AREX +2%, HRTG +2%,<br/>CHD +1.4%, ZUMZ +1.3%, (Zumiez Inc reports July same store sales -2.9% vs -7.6% Retail Metrics consensus; Q2 (Jul), sees Q2 EPS at high end or slightly better than prior guidance ($0.09)-(0.13) vs. ($0.09) Capital IQ Consensus Estimate primarily due to higher than planned sales), RIG +1.3%, LPI +1.3%, BLL +1.3%, MFC +1.3%, AGO +1.2%, FLXN +1%, HGG +0.9%, HRC +0.9%<br/><b>Other news:</b><br/>OCUL +23.6% (updates on its NDA for DEXTENZA; FDA issued a letter noting that corrective actions detailed in its responses as a whole appear to address the ten inspectional observations raised)<br/>ICLD +21.3% (receives over $6.0 million in new contracts and purchase orders for professional services, network services and maintenance for new and existing customers)<br/>CHEK +18.7% (enters into an agreement with GE Healthcare (GE) to develop and validate high-volume manufacturing for X-ray source production and assembly into its capsule)<br/>ANTH +6.4% (announces completion of dosing in CHABLIS-SC1 Phase 3 clinical study with Blisibimod )<br/>OMER +4.1% (announces results from its OMS906 complement program; OMS906 significantly reduced both incidence and severity of disease in a well-established animal model of arthritis mediated by the APC)<br/>MASI +3.6% (announces the CE marking for the pediatric indication for O3 regional oximetry with the O3 pediatric sensor)<br/>TOPS +3.1% ( enters into a senior secured facility with a major northern European bank for the financing of the M/T Nord Valiant)<br/>ZIOP +2.9% (announces the publication of data highlighting the benefits of using the non-viral Sleeping Beauty system to genetically modify T-cells to express a CAR for use against leukemias and lymphomas)<br/><b>Analyst comments:</b><br/>CELG +0.7% (upgraded to Buy from Neutral at BTIG Research)<br/>HSBC +0.7% (upgraded to Buy from Neutral at BofA/Merrill)<br/>APO +0.6% (upgraded to Outperform from Perform at Oppenheimer)<br/><br/><b>Gapping down<br/>In reaction to disappointing earnings/guidance:</b><br/>TDOC -24%, SGMO -22.7%, INOV -18.1%, BSQR -15.9%, TEGP -14.6%, BBRG -13.9%, FRSH -13.5%, QUIK -11%, GI -10.1%, (also files for $100 mln mixed securities shelf offering and 6,060,444 shares common stock offering by selling stockholders; announces recent FDA clearance and US launch of Lumos with Adaptive Matrix Imaging)<br/>NSYS -9.7%, UHAL -9.5%, IMGN -8.8%, AMRN -8.7%, AME -8.2%, HOS -7.9%, TRIP -7.2%, PMT -6.4%, FRGI -6.1%, CHK -5.3%, GPOR -5%, GOLD -4.9%, CF -4.8%, MET -4.5%, IRG -4.3%, VTAE -4.3%, ANDE -4.1%, LGCY -4%<br/>XOMA -3.9%, HIVE -3.8%, ALB -3.6%, ETP -3.6%, FOXA -3.5%, (also discloses that it eliminated the previously-announced suspension of voting rights of shares of Class B Common Stock held by stockholders who are not U.S. citizens ), ETE -3.4%, BDX -3.3%, CBPX -3.2%, (also expands share repurchase program to $100 mln from $50 mln), NOK -3.2%, LNC -3%, MED -2.9%, CTL -2.7%, ADRO -2.6%, TNK -2.4%, GERN -2.2%, G -2.1%, HSIC -2%<br/>PRU -1.9%, (also authorized a $500 mln increase to the existing share repurchase authorization for calendar year 2016), EVHC -1.9%, AGU -1.9%, TSO -1.9%, (also increases quarterly dividend), BLUE -1.8%, AWK -1.8%, NAVB -1.8%, DYN -1.7%, CXW -1.7%, LODE -1.7%<br/>PEGA -1.4%, SYNC -1.3%, CCOI -1.3%, HMHC -1.2%, SBH -1.2%, NLY -1.1%, CIM -1.1%, OAS -1.1%<br/><b>Other news:</b><br/>MNTA -14.8% (discontinues further accrual of its Phase 2 trial evaluating necuparanib in combination with Abraxane and gemcitabine in patients with advanced metastatic pancreatic cancer)<br/>PQ -9.5% ( in 10-Q adds a potential bankruptcy filing to list of risk factors - Was not part of 10-Q filed in May)<br/>AMRN -7.5% (announces that the FDA agreed to an amendment of its special protocol assessment agreement for the REDUCE-IT cardiovascular outcomes study)<br/>ADAP -4.9% (received notice from the FDA that a partial clinical hold has been placed on its planned pivotal study of NY-ESO SPEAR T-cell therapy in myxoid round cell liposarcoma )<br/>RYAM -4.7% (announces public offering of 1,250,000 shares of the Company's Series A Mandatory Convertible Preferred Stock)<br/>CP -3.3% (Canadian Pacific confirms the commencement of a public offering of 9,840,890 of common shares by certain funds managed by Pershing Square; Canadian Pacific and Canadian Natl Rail (CNI) agree to settle lawsuit commenced by CNI in August 2015 against CP, certain of its employees and an officer, alleging misuse of confidential information, without any admission of liability on the part of CP)<br/>PCLN -0.6% (following TRIP earnings)<br/>EXPE -0.5% (following TRIP earnings)<br/><b>Analyst comments:<br/></b>GRMN -1.6% ( downgraded to Underperform at BofA/Merrill)<br/><br/>Briefing.com